Erez Israeli, CEO of Dr. Reddy's, discusses the potential impact of Trump's proposed drug pricing changes, noting that ...

Brokerages' mixed review on Dr Reddy's higher than estimated earnings performance; cautiousness suggests recalibration of ...

Dr Reddy's, Navin Fluorine, Birla Corporation, Triveni Turbines, Shakti Pumps, Electrosteel Castings, Apollo Pipes. These ...

The sharp 250 basis points quarter-on-quarter decline in gross margin (the third consecutive sequential fall) reinforces ...

Dr. Reddy's Laboratories Ltd. closed 15.83% short of its 52-week high of 1,420.20 rupees, which the company achieved on August 21st.

Shares of Dr. Reddy’s Laboratories are on track to break through a critical range between ₹1,200 and ₹1,220 where surpassing ...

Emkay's latest report downgrades Dr. Reddy's Labs, citing significant margin misses in Q4FY25 despite higher other income and lower tax rates.

Pharma major Dr Reddy’s Laboratories Ltd’s consolidated net profit increased 21% in the fourth quarter ended March 31, 2025 ...

Dr Reddy was delivering a lecture on the science and promise of the gut microbiome at the CSIR–Indian Institute of Chemical ...

Dr Reddy's posted consolidated net profit growth of 21 per cent year-on-year to Rs 1,587 crore during the March quarter, ...

Dr. Reddy's Laboratories added 3.34% to Rs 1,193.75 after the company reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year ...

Stocks like Dr Reddy's Laboratories, Navin Fluorine International, Bank of India, Yes Bank, Swiggy, Manappuram Finance, ABB ...